咨询订购

点击这里给我发消息
Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

 $ USD

sales@raystarbio.com
You are here:Home-PROTACs-PROTAC

Request The Product List ofPROTAC PROTAC

Proteolysis targeting chimera (PROTAC) technology, the recruitment of E3 ubiquitin ligases to induce the degradation of a protein target, is rapidly impacting chemical biology, as well as modern drug development. 

PROTAC has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches.

PROTAC-induced protein degradation has yielded impressive preliminary efficacy in a limited number of cellular and in vivo systems but its broader utility and application in a clinical setting is yet to be tested.

 The flexibility of the approach is also being steadily expanded by the use of new ubiquitin E3 ligases. While most non-peptidic Protacs have used the E3 ligases VHL and cereblon, more recent reports have shown greater use of members of the IAP family of ligases. Mdm2 may also be a suitable ligase but has so far attracted fewer disclosures.

 Between the choices of E3 ligase ligand, the target-binding ligand and both the identity and attachment positions of the linker, there are a number of opportunities to design both very good, and very bad, Protacs in much the same way as with traditional small molecule medicinal chemistry.

PROTAC is now poised to answer some of its most critical questions to see if these novel scientific concepts can indeed translate to agents which deliver real clinical benefit and unprecedented medicine opportunities.

 

References:

1. Zengerle M, et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol. 2015 Aug 21;10(8):1770-7.

2. Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7.

3. Churcher I. Protac-induced Protein Degradation in Drug Discovery: Breaking the Rules-or Just Making New Ones?. J Med Chem. 2017 Nov 16. doi: 10.1021/acs.jmedchem.7b01272.

4. Ottis P, et al. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. ACS Chem Biol. 2017 Oct 20;12(10):2570-2578.

5. Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9.

Cat. No. Product Name CAS No. Information
GY10615

PROTAC K-Ras LC-2

PROTAC K-Ras LC-2 covalently binds KRASG12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRASG12C degrdn. leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines. LC-​2 demonstrates that PROTAC-​mediated degrdn. is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.
GY10613

PROTAC K-Ras Degrader-1

 		2378258-52-5

PROTAC K-Ras Degrader-1 (Compound 518) is potent K-Ras degrader based PROTAC, exhibits ≥70% degradation efficacy in SW1573 cells.
GY10612

CC-92480

 		2259648-80-9

CC-92480 is a cereblon E3 ubiquitin ligase modulating drug (CELMoD). CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity
GY10609

dFKBP-1

 		1799711-22-0

dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF of FKBP12, the Thalidomide based cereblon ligand and a linker.
GY10606

MD224

 		2136247-12-4

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells, and achieves an IC50 value of 1.5 nM in inhibition of growth of RS4;11 cells. MD-224 has the potential to be a new class of anticancer agent.
GY02942

ARV-771

 		1949837-12-0

ARV-771 is a potent BET degrader (PROTAC) in cellular models of CRPC; potently degrades BRD2/3/4 in 22Rv1 cells with DC50< 5 nM, equally potent activity in VCaP and LnCaP95 CRPC cell lines, causes depletion of c-MYC with IC50<1 nM; suppresses both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model.
GY02864

ARV-825

 		1818885-28-7

ARV-825 is a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 via the proteasome; shows more significant and longer lasting c-MYC suppression than small molecule inhibitors (JQ1, OTX015); leads to a superior effect on BL cells proliferation suppression.
GY02838

dBET1

 		1799711-21-9

dBET1 is a proteolysis-targeting chimera (PROTAC) molecule that appendes a competitive antagonist of BET bromodomain (JQ1) to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex; induces highly selective cereblon-dependent BET protein degradation in vitro (EC50=430 nM) and in vivo and delayed leukemia progression in mice.
GY02832

MZ1

 		1797406-69-9

MZ1 is a PROTAC that tethers JQ1 to a ligand for the E3 ubiquitin ligase VHL, triggers, induces degradation of the BET bromodomain BRD4; induces reversible, long-lasting, and unexpectedly selective removal of BRD4 over BRD2 and BRD3.
GY07132

CCT-367766

 		2229856-58-8

CCT-367766 (CCT367766) is a novel heterobifunctional PROTAC that binds and degrades the putative transcription factor regulator Pirin in cells.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use
浙ICP备18012073号-2